BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending
Executive Summary
FDA may consider returning generic buspirone ANDA approvals to tentative approval status as one option in light of an appellate court decision favoring Bristol-Myers Squibb in the BuSpar patent case.